Witjes - Figure 14
Conclusion: BCG is an issue in
FIG. 14: My conclusion from the first part of this presentation is that BCG is definitely a consideration in higher intermediate-risk NMI bladder cancer, in high-risk NMI bladder cancer (also discussed in Dr Shariat’s presentation), and in the highest risk BCG-failing patients (also discussed in Dr Kamat’s presentation). Obviously there will be some overlap with BCG non-responsive disease, and if no BCG is available or patients do not respond to BCG, then some of the treatment options will be similar.
(I did not cover all of the experimental issues; rather I tried to focus on those issues and solutions that will be practical in the very near future.)
